<DOC>
	<DOCNO>NCT02212886</DOCNO>
	<brief_summary>- This phase IIa study GA Depot 80 40mg administer IM injection subject RRMS 4 week interval 52 week treatment . - The purpose study assess safety , tolerability , efficacy monthly long-acting IM injection 80 40mg GA Depot subject RRMS . The study include subject switch daily thrice weekly administration 20 mg 40mg respectively glatiramer acetate ( GA , i.e. , Copaxone ) injection</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Monthly Long-acting IM Injection 80 40 mg GA Depot Subjects With RRMS</brief_title>
	<detailed_description>- 24 Subjects diagnosis relapse remit multiple sclerosis ( RRMS ) treat daily thrice weekly subcutaneous injection 20 mg 40 mg respectively GA ( Copaxone ) previous 12 month - Study product GA long-acting injection ( GA Depot ) combination extended-release microspheres injection diluent ( water injection ) parenteral use . GA Depot administer intramuscularly ( IM ) . - The study duration individual subject 60 week , consist 4 week screen evaluation ( week -4 0 ) , follow 52-week open-label treatment period , 4 week follow period : total 17 visit - Physical , vital sign safety assessment - visit - MRI visit 1 ( screening ) , week 24 , week 52 ( end treatment visit ) - Neurological safety laboratory test screen visit visit week 4 , 12 , 24 , 36 , 52 ( end treatment )</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>Male female subject diagnosis RRMS . Diagnosis multiple sclerosis ( MS ) consistent McDonald Criteria ( revision 2010 ) . Treatment 20 mg 40 mg GA ( Copaxone ) previous 12 month ongoing treatment Screening Visit . Normal renal function . Normal liver function . Normal hemoglobin concentration . Absence clinically significant medical , psychiatric laboratory abnormality . Ability provide write informed consent . Any relevant medical , surgical , psychiatric condition , laboratory value , concomitant medication , opinion investigator , make subject unsuitable study entry potentially unable complete aspect study . Severe anemia ( hemoglobin &lt; 10 g/dL ) . Abnormal renal function ( serum creatinine &gt; 1.5xULN ) . Pregnant breastfeed woman . Women capable child bearing must negative urine pregnancy test screen visit use adequate contraceptive method throughout study . Women surgically sterile ( hysterectomy tubal ligation ) whose last menstruation 12 month prior Screening Visit consider nonchildbearing potential . Acceptable form contraception include oral , implanted , injected contraceptive ; intrauterine device place least 3 month ; estrogen patch ; adequate barrier method conjunction spermicide . Abstinence consider acceptable contraceptive regimen . History anaphylactic reaction and/or serious allergic reaction follow vaccination , proven hypersensitivity component study drug , e.g . GA , polylacticcoglycolic acid ( PLGA ) , polyvinyl alcohol ( PVA ) . Known suspected history drug alcohol abuse . Positive test HIV , hepatitis , venereal disease research laboratory test ( VDRL ) , tuberculosis . Participation investigational drug study within 30 day prior start study . Treatment kind steroid last 30 day . Confirmed relapse last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Glatiramer acetate</keyword>
	<keyword>Copaxone</keyword>
	<keyword>Multiple sclerosis</keyword>
	<keyword>Relapsing remit multiple sclerosis</keyword>
	<keyword>RRMS</keyword>
	<keyword>GA Depot</keyword>
	<keyword>Monthly injection</keyword>
</DOC>